<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>
	Associations Between Fibrocytes and Postcontrast Myocardial T1 Times in
	Hypertrophic Cardiomyopathy
</title>
<meta name="viewport" content="initial-scale=1">
<link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:,b%7CRoboto+Condensed:b">
<link rel="stylesheet" href="../../all.css">
<link rel="stylesheet" href="../../screen.css" media="screen">
<script async src="https://inexorabletash.github.io/polyfill/keyboard.js"></script>
</head>
<body>
<header class="slide">
	<a href="http://jaha.ahajournals.org/" rel="external">
		<img class="logo" alt="J Am Heart Assoc" src="AHA.svg">
	</a>
	<h1>
		<a href="https://doi.org/10.1161/JAHA.113.000270" rel="external">
			Associations Between Fibrocytes and Postcontrast Myocardial
			T<sub>1</sub> Times in Hypertrophic Cardiomyopathy
		</a>
	</h1>
	<ol class="authors">
		<li>Lu Fang</li>
		<li>Anna Beale</li>
		<li>Andris H. Ellims</li>
		<li>Xiao‐lei Moore</li>
		<li>Liang‐han Ling</li>
		<li>Andrew J. Taylor</li>
		<li>Jaye Chin‐Dusting</li>
		<li>Anthony M. Dart</li>
	</ol>
	<dl>
		<dt>Speaker</dt>
		<dd><a href="http://jdh8.org/" rel="author">Chen-Pang He</a></dd>
		<dt>Advisor</dt>
		<dd>Li-Chern Pan</dd>
	</dl>
</header>
<section class="slide">
	<h2>Overview</h2>
	<dl>
		<dt>Background</dt>
		<dd>Fibrocytes are linked to various fibrotic disorders.</dd>
		<dd>Do they cause myocardial fibrosis?</dd>
		<dt>Result</dt>
		<dd>
			<abbr title="hypertrophic cardiomyopathy">HCM</abbr> patients with
			diffuse fibrosis have
			<ul>
				<li>
					Elevated plasma
					<abbr title="stromal cell-derived factor">SDF</abbr>
				</li>
				<li>
					Enhanced ability of
					<abbr title="peripheral blood mononuclear cell">PBMC</abbr>s
					to differentiate into fibrocytes.
				</li>
			</ul>
		</dd>
		<dt>Conclusion</dt>
		<dd>
			Fibrocytes may contribute to the pathogenesis of myocardial
			fibrosis.
		</dd>
	</dl>
</section>
<section class="slide">
	<h2>
		Myocardial fibrosis and
		<abbr title="hypertrophic cardiomyopathy">HCM</abbr>
	</h2>
	<p><strong>Myocardial fibrosis</strong> contributes to</p>
	<ul>
		<li>Heart failure</li>
		<li>Increased risk for arrythmias and sudden death.</li>
	</ul>
	<dl>
		<dt>Hypertrophic cardiomyopathy</dt>
		<dd>
			Unexplained left ventricular hypertrophy
			<ul class="small"><li>Non‐dilated ventricular chambers</li></ul>
		</dd>
		<dd>
			Diffuse and focal fibroses are common features.
			<ul class="small"><li>Poor prognosis</li></ul>
		</dd>
		<dd>Pathogenesis not completely understood</dd>
	</dl>
</section>
<table class="slide">
	<caption>Table 1: Patient demographics</caption>
	<thead>
	<tr>
		<th></th>
		<th>Control</th>
		<th>T<sub>1</sub>≥470
		</th>
		<th>T<sub>1</sub>&lt;470
		</th>
	</tr>
	</thead>
	<tbody>
	<tr>
		<td>n</td>
		<td>20</td>
		<td>21</td>
		<td>16</td>
	</tr>
	<tr>
		<td>Gender, m/f</td>
		<td>14/6</td>
		<td>13/8</td>
		<td>14/2</td>
	</tr>
	<tr>
		<td>Age, y</td>
		<td>46±13</td>
		<td>49.6±14.6</td>
		<td>48.7±13.8</td>
	</tr>
	<tr>
		<td>Body mass index, kg/m<sup>2</sup></td>
		<td>22.6±2.2</td>
		<td>26.6±4.7**</td>
		<td>28±4.0***</td>
	</tr>
	</tbody>
	<tbody>
	<tr>
		<th colspan="4">Full Blood Count</th>
	</tr>
	<tr>
		<td>Haemoglobin, g/L</td>
		<td>144.7±9.7</td>
		<td>144.1±11.4</td>
		<td>149.1±17.6</td>
	</tr>
	<tr>
		<td>Platelets, 10<sup>9</sup>/L
		</td>
		<td>219.2±42.5</td>
		<td>207.2±53.6</td>
		<td>212.5±62.1</td>
	</tr>
	<tr>
		<td>Hematocrit, L/L</td>
		<td>0.42±0.03</td>
		<td>0.42±0.03</td>
		<td>0.43±0.05</td>
	</tr>
	<tr>
		<td>White blood cells, 10<sup>9</sup>/L
		</td>
		<td>5.78±1.23</td>
		<td>7.27±2.50*</td>
		<td>8.39±1.97**</td>
	</tr>
	<tr>
		<td>Neutrophils, 10<sup>9</sup>/L
		</td>
		<td>3.26±1.04</td>
		<td>4.75±2.18*</td>
		<td>5.53±1.90**</td>
	</tr>
	<tr>
		<td>Lymphocytes, 10<sup>9</sup>/L
		</td>
		<td>1.91±0.56</td>
		<td>1.87±0.61</td>
		<td>2±0.55</td>
	</tr>
	<tr>
		<td>Monocytes, 10<sup>9</sup>/L
		</td>
		<td>0.39±0.12</td>
		<td>0.51±0.17*</td>
		<td>0.53±0.16*</td>
	</tr>
	<tr>
		<td>Monocytes, % of WBC</td>
		<td>6.84±1.84</td>
		<td>7.28±1.89</td>
		<td>6.48±1.50</td>
	</tr>
	</tbody>
</table>
<section class="slide">
	<h2>Identification of myocardial fibrosis</h2>
	<dl>
		<dt>
			Postcontrast myocardial
			<abbr title="longitudinal relaxation time">T<sub>1</sub></abbr>
			mapping
		</dt>
		<dd>
			A <abbr title="cardiac magnetic resonance">CMR</abbr> technique to
			evaluate myocardial fibrosis
		</dd>
		<dd>
			Short T<sub>1</sub> times are consistent with diffuse myocardial
			fibrosis.
			<ul class="small"><li>Correlated with worsening diastolic dysfunction</li></ul>
		</dd>
	</dl>
	<p>
		T<sub>1</sub> times were sigificantly lower in <abbr
		title="hypertrophic cardiomyopathy">HCM</abbr> patients.
	</p>
</section>
<section class="slide">
	<h2>Figure 1</h2>
	<ol class="A">
		<li>
			Correlation between postcontrast myocardial T<sub>1</sub> times and
			mean E/e′
		</li>
		<li>Circulating markers of collagen turnover</li>
	</ol>
	<dl>
		<dt>PINP</dt>
		<dd>Aminoterminal propeptide of type I collagen</dd>
		<dt>PIIINP</dt>
		<dd>Aminoterminal propeptide of type III collagen</dd>
	</dl>
</section>
<img class="slide" src="http://jaha.ahajournals.org/content/2/5/e000270/F1.large.jpg" alt="
	Correlation between postcontrast myocardial T1 times and mean E/e′ and
	circulating markers of collagen turnover. A, T1 time (measured by CMR) was
	inversely correlated with mean E/e′ (measured by echocardiograph), r=−0.57,
	P<0.001. B, Circulating markers of collagen turnover. Data were expressed
	as mean±SEM. CMR indicates cardiac magnetic resonance; PINP, aminoterminal
	propeptide of type I collagen, PIIINP, amino terminal propeptide of type
	III collagen; SEM, standard error of the mean.">
<table class="slide">
	<caption>Table 2a: <abbr title="cardiac magnetic resonance">CMR</abbr> data</caption>
	<thead>
		<tr>
			<th></th>
			<th>Control (20)</th>
			<th>T<sub>1</sub>≥470 (21)
			</th>
			<th>T<sub>1</sub>&lt;470 (16)
			</th>
		</tr>
	</thead>
	<tbody>
		<tr>
			<td>T<sub>1</sub> times (ms), excluding LGE
			</td>
			<td>568.5±49.2</td>
			<td>540.9±68.1</td>
			<td>434.8±28.9***<sup>,</sup> <sup>†††</sup></td>
		</tr>
		<tr>
			<td>T<sub>1</sub> times (ms), including LGE
			</td>
			<td>568.5±49.2</td>
			<td>529.2±76.7</td>
			<td>427.2±30.6***<sup>,</sup> <sup>†††</sup></td>
		</tr>
		<tr>
			<td>T<sub>1</sub> times (ms, corrected values)
			</td>
			<td>550±47.5</td>
			<td>519.2±75.4</td>
			<td>417.2±32.9***<sup>,</sup> <sup>†††</sup></td>
		</tr>
		<tr>
			<td>Blood T<sub>1</sub> times, ms
			</td>
			<td>306±21.5</td>
			<td>308.1±32.5</td>
			<td>299.9±24.2</td>
		</tr>
		<tr>
			<td>Septal thickness, mm</td>
			<td>8.3±1.6</td>
			<td>18.9±6.2***</td>
			<td>18.7±3.6***</td>
		</tr>
		<tr>
			<td>Lateral wall thickness, mm</td>
			<td>7.8±1.2</td>
			<td>8.4±1.9</td>
			<td>8.5±2.1</td>
		</tr>
		<tr>
			<td>Septal/lateral wall thickness</td>
			<td>1.06±0.09</td>
			<td>2.29±0.54***</td>
			<td>2.29±0.49***</td>
		</tr>
		<tr>
			<td>LV mass index, g/BSA</td>
			<td>51.4±8.9</td>
			<td>86.6±37.8**</td>
			<td>104.4±31.5***</td>
		</tr>
		<tr>
			<td>LV ejection fraction, %</td>
			<td>64.2±4.6</td>
			<td>68.1±6.2</td>
			<td>70±8.6</td>
		</tr>
		<tr>
			<td>Presence of LGE, %</td>
			<td>NA</td>
			<td>85.7</td>
			<td>87.5</td>
		</tr>
		<tr>
			<td>Quantity of LGE (% of LV) mass</td>
			<td>NA</td>
			<td>5.6±7.8</td>
			<td>5.3±6.7</td>
		</tr>
	</tbody>
</table>
<table class="slide">
	<caption>Table 2b: Echocardiography data</caption>
	<thead>
		<tr>
			<th></th>
			<th>Control (18)</th>
			<th>T<sub>1</sub>≥470 (13)
			</th>
			<th>T<sub>1</sub>&lt;470 (14)
			</th>
		</tr>
	</thead>
	<tbody>
		<tr>
			<td>Left atrial volume indexed, mL/m<sup>2</sup></td>
			<td>27.6±8.9</td>
			<td>40.8±9.0**</td>
			<td>46.8±16.9***</td>
		</tr>
		<tr>
			<td>E/A ratio</td>
			<td>1.38±0.36</td>
			<td>1.11±0.35</td>
			<td>1.41±0.39<sup>†</sup></td>
		</tr>
		<tr>
			<td>Deceleration time, ms</td>
			<td>182.1±27.0</td>
			<td>188±45.7</td>
			<td>232.5±47.1*</td>
		</tr>
		<tr>
			<td>Septal e′, cm/s</td>
			<td>10.6±2.9</td>
			<td>6.3±1.6***</td>
			<td>6.1±1.9***</td>
		</tr>
		<tr>
			<td>Lateral e′, cm/s</td>
			<td>13.7±3.5</td>
			<td>8.8±2.8**</td>
			<td>8.2±3.5***</td>
		</tr>
		<tr>
			<td>Mean e′, cm/s</td>
			<td>11.9±3.0</td>
			<td>7.5±1.9***</td>
			<td>7±2.5***</td>
		</tr>
		<tr>
			<td>Septal E/e′</td>
			<td>8.5±2.6</td>
			<td>11.9±3.9</td>
			<td>14.3±5.6**</td>
		</tr>
		<tr>
			<td>Lateral E/e′</td>
			<td>6.3±1.9</td>
			<td>8.7±2.8</td>
			<td>11.8±6.1**</td>
		</tr>
		<tr>
			<td>Mean E/e′</td>
			<td>7.8±2.6</td>
			<td>10.6±3.0</td>
			<td>13.1±5.3**</td>
		</tr>
		<tr>
			<td>Resting LVOT gradient, mm Hg</td>
			<td>5.2±1.2</td>
			<td>32±43.8*</td>
			<td>36.2±45.9*</td>
		</tr>
	</tbody>
</table>
<figure class="slide">
	<figcaption>Figure 2: Measurement of circulating fibrocytes</figcaption>
	<img src="http://jaha.ahajournals.org/content/2/5/e000270/F2.large.jpg" alt="
		A, Representative flow cytometric analysis of circulating fibrocytes.
		(a) Total cells acquired; (b) CD45+ cells; (c) Isotype control for
		collagen I and CD34 set on CD45+ cells; (d) Positive staining for
		collagen I and CD34 set on CD45+ cells; B, Circulating fibrocytes in
		patients with postcontrast myocardial T1<470 ms (n=16), patients with
		T1≥470 ms (n=21), and healthy controls (Ctrl, n=20). (a) The percentage
		of fibrocytes relative to white blood cells (WBC, i.e. CD45+); (b) the
		concentration of fibrocytes per microliter of blood. Data were
		expressed as mean±SEM (standard error of the mean). *P<0.05. APC
		indicates allophycocyanin; FITC, fluorescein isothiocyanate; FSC,
		forward scatter; PE, phycoerythrin; SSC, side scatter.">
</figure>
<figure class="slide">
	<figcaption>
		Figure 3: Differentiation of fibrocytes from
		<abbr title="peripheral blood mononuclear cell">PBMC</abbr>s
	</figcaption>
	<img src="http://jaha.ahajournals.org/content/2/5/e000270/F3.large.jpg" alt="
		A, Pictures of fibrocytes appeared as spindle‐shaped cells developed
		from PBMC culture for 13 days (under ×40). B, Representative of flow
		cytometric dotplots of cells stained with CD45 and collagen I (left:
		isotype control, right: antibody staining) and double‐positive cells
		are fibrocytes. C, The percentage of fibrocytes from PBMC culture
		relative to the remaining adherent cells in HCM patients with
		postcontrast myocardial T1 time <470 ms, with T1 time ≥470 ms and
		healthy controls (Ctrl) (n=16, 21, and 20, respectively). D,
		Correlation between cultured fibrocytes and T1 time. Data were
		expressed as mean±SEM. *P<0.05; ***P<0.001. HCM indicates hypertrophic
		cardiomyopathy; PBMCs, peripheral blood mononuclear cells; SEM,
		standard error of the mean.">
</figure>
<figure class="slide">
	<figcaption>Figure 4: Gene expression of matrix proteins and chemokine receptors</figcaption>
	<img src="http://jaha.ahajournals.org/content/2/5/e000270/F4.large.jpg" alt="
		Gene expression of collagen I (A), vimentin (B) and fibronectin (C),
		and CXCR4 (D) of the remaining adherent cells after PBMC culture for 13
		days was measured by real‐time PCR in HCM patients with postcontrast
		myocardial T1 time <470 ms, with T1 time ≥470 ms and healthy controls
		(Ctrl) (n=11, 6, and 14, respectively). Data were expressed as
		mean±SEM. *P<0.05. HCM indicates hypertrophic cardiomyopathy; PBMC,
		peripheral blood mononuclear cell; PCR, polymerase chain reaction; SEM,
		standard error of the mean.">
</figure>
<figure class="slide">
	<figcaption>Figure 5: Changes of plasma chemokines/cytokines</figcaption>
	<img src="http://jaha.ahajournals.org/content/2/5/e000270/F5.large.jpg" alt="
		Plasma levels of cytokines and chemokines mediating fibrocyte
		trafficking (A) and differentiation (B) were measured by multiplex
		assay in HCM patients with postcontrast myocardial T1 time <470 ms,
		with T1 time ≥470 ms and healthy controls (Ctrl) (n=16, 21, and 20,
		respectively). Data were expressed as mean±SEM. *P<0.05. HCM indicates
		hypertrophic cardiomyopathy; IFNγ, interferon γ; IL‐4, interleukin‐4;
		IL‐12, interleukin‐12; IL‐13, interleukin‐13; MCP‐1, monocyte
		chemoattractant protein‐1; SAP, serum amyloid P; SDF‐1, stromal‐derived
		factor‐1; SLC, secondary lymphoid cytokine; TGFβ, transforming growth
		factor β; SEM, standard error of the mean.">
</figure>
<section class="slide">
	<h2>Limitations</h2>
	<ol>
		<li>
			Postcontrast myocardial T<sub>1</sub> times are also affected by
			other factors that may expand the extracellular matrix.
		</li>
		<li>The sample size is relatively small</li>
	</ol>
</section>
<section class="slide">
	<h2>Levels of evidence</h2>
	<ol>
		<li class="blur">Randomized controlled trials</li>
		<li class="blur">Cohort studies</li>
		<li>Case-control studies</li>
		<li class="blur">Case-series</li>
		<li class="blur">Expert opinion</li>
	</ol>
</section>
<script async src="../../s5.js"></script>
</body>
</html>
